🟢 Amgen is trading 3.85% up in pre-market after beating Q3 estimates

Amgen is trading at $479.04, up 3.85%, after third-quarter revenue rose 8% to $10.37 billion, beating analyst expectations. - Adjusted EPS was $6.45. Amgen raised 2026 revenue guidance to $38.9–$39.7 billion and adjusted EPS guidance to $22.90–$23.70. - Record quarterly Repatha sales reached $1.085 billion, up 37% year over year. - Shares reportedly slipped after hours following the report, reversing into the pre-market gain; price context includes no trading-volume data.